Status:
UNKNOWN
Prospective Assay for SARS-CoV-2 (COVID-19) Antibody Detection Indirectly by Immunofluorescence: SARS-CoV2 IIF Method
Lead Sponsor:
Szeged University
Collaborating Sponsors:
Bilogical Research Centre, Szeged
Conditions:
Sars-CoV2
Eligibility:
All Genders
18+ years
Brief Summary
Prospective assay for SARS-CoV-2 antibody detection indirectly by immunofluorescence: SARS-CoV2 IIF method
Detailed Description
Sample preparation, serum separation by centrifugation * 100 µl of serum for standard SARS-CoV2 ELISA is used according to the instructions for use. * 100 µl of serum indirect immunofluorescent (IIF)...
Eligibility Criteria
Inclusion
- Person over 18 years of age
- Signing a package leaflet and a informal consent
- In the case of a positive group, confirmed by SARS-CoV2 qPCR Patient with COVID-19 or recovered individual.
- In case of negative group by SARS-CoV2 qPCR test 2 negative in COVID-19 suffering individual
Exclusion
- Refuses to sign the consent form
Key Trial Info
Start Date :
May 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04429620
Start Date
May 30 2020
End Date
December 31 2020
Last Update
June 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Szeged, Albert Szent-Györgyi Health Center
Szeged, Hungary